List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1718981/publications.pdf Version: 2024-02-01



SHUANGLUU

#	Article	IF	CITATIONS
1	A Famous Chinese Medicine Formula: Yinhuo Decoction Antagonizes the Damage of Corticosterone to PC12 Cells and Improves Depression by Regulating the SIRT1/PGC-1α Pathway. BioMed Research International, 2022, 2022, 1-13.	1.9	1
2	99mTc-3SPboroxime: A neutral 99mTc(III) radiotracer with high heart uptake and long myocardial retention. Journal of Nuclear Cardiology, 2021, 28, 2687-2696.	2.1	4
3	Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clinical Immunology, 2021, 230, 108793.	3.2	91
4	Facile construction of N-doped carbon nanotubes encapsulating Co nanoparticles as a highly efficient multifunctional catalyst for electrochemical reactions. CrystEngComm, 2021, 23, 1671-1676.	2.6	7
5	The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology, 2020, 80, 106210.	3.8	424
6	68Ga-labeled dimeric and trimeric cyclic RGD peptides as potential PET radiotracers for imaging gliomas. Applied Radiation and Isotopes, 2019, 148, 168-177.	1.5	9
7	The efficacy of RGD modified liposomes loaded with vinorelbine plus tetrandrine in treating resistant brain glioma. Journal of Liposome Research, 2019, 29, 21-34.	3.3	26
8	New 99mTc Radiotracers for Myocardial Perfusion Imaging by SPECT. Current Radiopharmaceuticals, 2019, 12, 171-186.	0.8	5
9	Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 616-628.	2.8	42
10	Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels. Journal of Drug Targeting, 2018, 26, 793-805.	4.4	32
11	Sulfonyl-Containing Boronate Caps for Optimization of Biological Properties of <sup>99m</sup> Tc(III) Radiotracers [ <sup>99m</sup> TcCl(CDO)(CDOH) <sub>2</sub> B-R] (CDOH <sub>2</sub> =) Tj ETQq1 1 0.7843	31 <b>6.4</b> gBT /	O <b>v</b> erlock 10
12	Molecular Imaging in Targeted Therapeutics. Contrast Media and Molecular Imaging, 2018, 2018, 1-2.	0.8	3
13	Preparation, characterization and in vivo evaluation of a formulation of dantrolene sodium with hydroxypropyl-β-cyclodextrin. Journal of Pharmaceutical and Biomedical Analysis, 2017, 135, 153-159.	2.8	15
14	Seco-sativene and Seco-longifolene Sesquiterpenoids from Cultures of Endophytic Fungus Bipolaris eleusines. Natural Products and Bioprospecting, 2017, 7, 147-150.	4.3	13
15	The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer. Journal of Drug Targeting, 2017, 25, 541-553.	4.4	10
16	Iminodiacetic acid as bifunctional linker for dimerization of cyclic RGD peptides. Nuclear Medicine and Biology, 2017, 48, 1-8.	0.6	5
17	<sup>99m</sup> Tc-3Cboroxime: a novel <sup>99m</sup> Tc( <scp>iii</scp> ) complex [ <sup>99m</sup> TcCl(CDO)(CDOH) <sub>2</sub> B-3C] (CDOH <sub>2</sub> = cyclohexanedione) Tj ETQq1 1 mvocardial retention. Dalton Transactions. 2017. 46, 14509-14518	0,784314	rgBT /Over
18	Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. European Journal of Pharmaceutical Sciences, 2017, 106, 185-197.	4.0	28

#	Article	IF	CITATIONS
19	Novel Approach for <sup>99m</sup> Tc-Labeling of Red Blood Cells: Evaluation of <sup>99m</sup> Tc-4SAboroxime as a Blood Pool Imaging Agent. Bioconjugate Chemistry, 2017, 28, 2998-3006.	3.6	5
20	Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG 2000 -transferrin in treatment of brain glioma. European Journal of Pharmaceutical Sciences, 2017, 96, 129-140.	4.0	67
21	Clinical study of 99mTc-3P-RGD2 peptide imaging in osteolytic bone metastasis. Oncotarget, 2017, 8, 75587-75596.	1.8	12
22	Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. International Journal of Nanomedicine, 2017, Volume 12, 7433-7451.	6.7	53
23	Novel 99m Tc(III)-azide complexes [ 99m Tc(N 3 )(CDO)(CDOH) 2 B-R] (CDOH 2 = cyclohexanedione) Tj ETQq1	1 0,7843	14 rgBT /Over
24	Novel <sup>99m</sup> Tc(III) Complexes [ <sup>99m</sup> TcCl(CDO)(CDOH) <sub>2</sub> B–R] (CDOH <sub>2</sub> = Cyclohexanedione Dioxime) Useful as Radiotracers for Heart Imaging. Bioconjugate Chemistry, 2016, 27, 2770-2779.	3.6	8
25	Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophysics Reports, 2016, 2, 1-20.	0.8	64
26	Comparison of biological properties of 99m Tc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging. Nuclear Medicine and Biology, 2016, 43, 661-669.	0.6	25
27	Impact of Boronate Capping Groups on Biological Characteristics of Novel <sup>99m</sup> Tc(III) Complexes [ <sup>99m</sup> TcCl(CDO)(CDOH) <sub>2</sub> B-R] (CDOH <sub>2</sub> =) Tj ETQq1 1 0.7843	3143.gBT /	Overlock 10
28	Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins. Bioconjugate Chemistry, 2015, 26, 1413-1438.	3.6	89
29	Comparison of biological properties of 111In-labeled dimeric cyclic RGD peptides. Nuclear Medicine and Biology, 2015, 42, 137-145.	0.6	13
30	Development of kit formulations for <sup>99m</sup> TcNâ€MPO: a cationic radiotracer for myocardial perfusion imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 584-592.	1.0	7
31	FITC-Conjugated Cyclic RGD Peptides as Fluorescent Probes for Staining Integrin α <sub>v</sub> β <sub>3</sub> /α <sub>v</sub> β <sub>5</sub> in Tumor Tissues. Bioconjugate Chemistry, 20 25, 1925-1941.	14,3.6	68
32	Effect of co-ligands on chemical and biological properties of 99mTc(III) complexes [99mTc(L)(CDO)(CDOH)2BMe] (L=Cl, F, SCN and N3; CDOH2=cyclohexanedione dioxime). Nuclear Medicine and Biology, 2014, 41, 813-824.	0.6	9
33	Impact of Multiple Negative Charges on Blood Clearance and Biodistribution Characteristics of <sup>99m</sup> Tc-Labeled Dimeric Cyclic RGD Peptides. Bioconjugate Chemistry, 2014, 25, 1720-1729.	3.6	17
34	<sup>99m</sup> Tc-Galacto-RGD <sub>2</sub> : A Novel <sup>99m</sup> Tc-Labeled Cyclic RGD Peptide Dimer Useful for Tumor Imaging. Molecular Pharmaceutics, 2013, 10, 3304-3314.	4.6	38
35	Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrin <i>α</i> <sub>v</sub> <i>β</i> <sub>3</sub> –Targeted Radiotracer <sup>99m</sup> Tc-3P-RGD <sub>2</sub> . Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 251-258.	2.5	25
36	Efficient proteolysis strategies based on microchip bioreactors. Journal of Proteomics, 2013, 82, 1-13.	2.4	19

#	Article	IF	CITATIONS
37	Evaluation of K(HYNIC) <sub>2</sub> as a Bifunctional Chelator for <sup>99m</sup> Tc-Labeling of Small Biomolecules. Bioconjugate Chemistry, 2013, 24, 701-711.	3.6	14
38	Integrin α <sub>v</sub> l² <sub>3</sub> -Targeted Radiotracer <sup>99m</sup> Tc-3P-RGD <sub>2</sub> Useful for Noninvasive Monitoring of Breast Tumor Response to Antiangiogenic Linifanib Therapy but not Anti-Integrin α <sub>v</sub> l² <sub>3</sub> RGD <sub>2</sub> Therapy. Theranostics, 2013, 3, 816-830.	10.0	27
39	Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin $\hat{I}\pm \nu\hat{I}^23.$ Molecular Imaging, 2013, 12, 39-48.	1.4	19
40	Multimeric Cyclic RGD Peptides Useful for Development of Integrin α <sub>v</sub> β <sub>3</sub> -Targeted SPECT Radiotracers. , 2012, , 165-195.		0
41	Evaluation of <sup>99m</sup> Tc-Labeled Cyclic RGD Dimers: Impact of Cyclic RGD Peptides and <sup>99m</sup> Tc Chelates on Biological Properties. Bioconjugate Chemistry, 2012, 23, 586-595.	3.6	29
42	Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α <sub>v</sub> β <sub>3</sub> -Targeted Radiotracer <sup> 99m</sup> Tc-3P-RGD <sub>2</sub> . Theranostics, 2012, 2, 577-588.	10.0	35
43	99mTc-centered one-pot synthesis for preparation of 99mTc radiotracers. Dalton Transactions, 2011, 40, 6077.	3.3	62
44	<sup>64</sup> Cu-Labeled Phosphonium Cations as PET Radiotracers for Tumor Imaging. Bioconjugate Chemistry, 2011, 22, 1459-1472.	3.6	47
45	Evaluation of <sup>111</sup> In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability. Theranostics, 2011, 1, 322-340.	10.0	47
46	Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics, 2011, 1, 58-82.	10.0	124
47	Evaluation of 99 mTcN-MPO as a New Myocardial Perfusion Imaging Agent in Normal Dogs and in an Acute Myocardial Infarction Canine Model: Comparison with 99 mTc-Sestamibi. Molecular Imaging and Biology, 2011, 13, 121-127.	2.6	15
48	Blood Clearance Kinetics, Biodistribution, and Radiation Dosimetry of a Kit-Formulated Integrin αvβ3-Selective Radiotracer 99mTc-3PRGD2 in Non-Human Primates. Molecular Imaging and Biology, 2011, 13, 730-736.	2.6	69
49	MicroPET Imaging of Integrin αvβ3 Expressing Tumors Using 89Zr-RGD Peptides. Molecular Imaging and Biology, 2011, 13, 1224-1233.	2.6	50
50	Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers. Amino Acids, 2011, 41, 1059-1070.	2.7	27
51	<sup>99m</sup> Tc-Labeled Cyclic RGD Peptides for Noninvasive Monitoring of Tumor Integrin α <sub>v</sub> β <sub>3</sub> Expression. Molecular Imaging, 2011, 10, 7290.2011.00006.	1.4	58
52	Kinetic characterization of a novel cationic 99mTc(l)-tricarbonyl complex, 99mTc-15C5-PNP, for myocardial perfusion imaging. Journal of Nuclear Cardiology, 2010, 17, 858-867.	2.1	18
53	99mTc and 1111n-Labeling of Small Biomolecules: Bifunctional Chelators and Related Coordination Chemistry. Current Topics in Medicinal Chemistry, 2010, 10, 1113-1134.	2.1	26
54	Evaluation of <sup>111</sup> In-Labeled Cyclic RGD Peptides: Tetrameric not Tetravalent. Bioconjugate Chemistry, 2010, 21, 969-978.	3.6	51

#	Article	IF	CITATIONS
55	Minimizing liver uptake of cationic 99mTc radiotracers with ether and crown ether functional groups. World Journal of Hepatology, 2010, 2, 21.	2.0	17
56	Mechanism for myocardial localization and rapid liver clearance of Tc-99m-N-MPO: A new perfusion radiotracer for heart imaging. Journal of Nuclear Cardiology, 2009, 16, 571-579.	2.1	29
57	68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 947-957.	6.4	132
58	Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1296-1307.	6.4	115
59	99mTcO(MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1874-1884.	6.4	42
60	Improving Tumor-Targeting Capability and Pharmacokinetics of <sup>99m</sup> Tc-Labeled Cyclic RGD Dimers with PEG <sub>4</sub> Linkers. Molecular Pharmaceutics, 2009, 6, 231-245.	4.6	136
61	2-Mercaptoacetylglycylglycyl (MAG <sub>2</sub> ) as a Bifunctional Chelator for <sup>99m</sup> Tc-Labeling of Cyclic RGD Dimers: Effect of Technetium Chelate on Tumor Uptake and Pharmacokinetics. Bioconjugate Chemistry, 2009, 20, 1559-1568.	3.6	34
62	Improving Tumor Uptake and Pharmacokinetics of64Cu-Labeled Cyclic RGD Peptide Dimers with Gly3and PEG4Linkers. Bioconjugate Chemistry, 2009, 20, 750-759.	3.6	123
63	Radiolabeled Cyclic RGD Peptides as Integrin α <sub>v</sub> l² <sub>3</sub> -Targeted Radiotracers: Maximizing Binding Affinity via Bivalency. Bioconjugate Chemistry, 2009, 20, 2199-2213.	3.6	315
64	The Missed Tc-99m Radiopharmaceuticals for Cardiac Imaging. Current Radiopharmaceuticals, 2009, 2, 268-276.	0.8	2
65	Tc-99m-N-MPO: Novel cationic Tc-99m radiotracer for myocardial perfusion imaging. Journal of Nuclear Cardiology, 2008, 15, 535-546.	2.1	35
66	Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Advanced Drug Delivery Reviews, 2008, 60, 1347-1370.	13.7	349
67	Coligand effects on the solution stability, biodistribution and metabolism of the 99mTc-labeled cyclic RGDfK tetramer. Nuclear Medicine and Biology, 2008, 35, 111-121.	0.6	38
68	<sup>99m</sup> Tc-Labeling of HYNIC-Conjugated Cyclic RGDfK Dimer and Tetramer Using EDDA as Coligand. Bioconjugate Chemistry, 2008, 19, 634-642.	3.6	33
69	Linker Effects on Biological Properties of 111In-Labeled DTPA Conjugates of a Cyclic RGDfK Dimer. Bioconjugate Chemistry, 2008, 19, 201-210.	3.6	47
70	Improving Tumor Uptake and Excretion Kinetics of <sup>99</sup> <sup>m</sup> Tc-Labeled Cyclic Arginine-Glycine-Aspartic (RGD) Dimers with Triglycine Linkers. Journal of Medicinal Chemistry, 2008, 51, 7980-7990.	6.4	115
71	Evaluation of 99mTcN-15C5 as a new myocardial perfusion imaging agent in normal dogs and canines with coronary stenosis. Nuclear Medicine Communications, 2008, 29, 775-781.	1.1	12
72	Effects of linker variation on the in vitro and in vivo characteristics of an 1111n-labeled RGD peptide. Nuclear Medicine and Biology, 2007, 34, 29-35.	0.6	76

#	Article	IF	CITATIONS
73	Evaluation of a99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer. Bioconjugate Chemistry, 2007, 18, 438-446.	3.6	126
74	Ether and crown ether-containing cationic 99mTc complexes useful as radiopharmaceuticals for heart imaging. Dalton Transactions, 2007, , 1183.	3.3	50
75	Impact of Bidentate Chelators on Lipophilicity, Stability, and Biodistribution Characteristics of Cationic99mTc-Nitrido Complexes. Bioconjugate Chemistry, 2007, 18, 929-936.	3.6	33
76	Improved targeting of the αvl²3 integrin by multimerisation of RGD peptides. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 267-273.	6.4	195
77	Impact of PKM Linkers on Biodistribution Characteristics of the99mTc-Labeled Cyclic RGDfK Dimer. Bioconjugate Chemistry, 2006, 17, 1499-1507.	3.6	34
78	Structureâ^'Activity Relationships of 111In- and 99mTc-Labeled Quinolin-4-one Peptidomimetics as Ligands for the Vitronectin Receptor:  Potential Tumor Imaging Agents. Bioconjugate Chemistry, 2006, 17, 1294-1313.	3.6	29
79	A Novel Ternary Ligand System Useful for Preparation of Cationic99mTc-Diazenido Complexes and99mTc-Labeling of Small Biomolecules. Bioconjugate Chemistry, 2006, 17, 473-484.	3.6	28
80	99mTc-Labeled Cyclic RGDfK Dimer:Â Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3Expression. Bioconjugate Chemistry, 2006, 17, 1069-1076.	3.6	65
81	Evaluation of novel cationic 99mTc-nitrido complexes as radiopharmaceuticals for heart imaging: improving liver clearance with crown ether groups. Nuclear Medicine and Biology, 2006, 33, 419-432.	0.6	42
82	Evaluation of novel cationic 99mTc(I)–tricarbonyl complexes as potential radiotracers for myocardial perfusion imaging. Nuclear Medicine and Biology, 2006, 33, 1045-1053.	0.6	37
83	Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging. Molecular Pharmaceutics, 2006, 3, 472-487.	4.6	310
84	Synthesis and Characterization of Cr(III) Complexes with 3â€Hydroxyâ€4â€Pyrones and 1,2â€Dimethylâ€3â€Hydroxyâ€4â€Pyridinone (DMHP): Xâ€Ray Crystal Structures of Cr(DMHP)3 · 1: Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 2005, 35, 61-70.	2H2 <b>0.a</b> nd (	Cr(øna)3.
85	Effect of Coligands on Biodistribution Characteristics of Ternary Ligand 99mTc Complexes of a HYNIC-Conjugated Cyclic RGDfK Dimer. Bioconjugate Chemistry, 2005, 16, 1580-1588.	3.6	54
86	microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. Journal of Nuclear Medicine, 2005, 46, 1707-18.	5.0	251
87	90Y and 111In Complexes of a DOTA-Conjugated Integrin αvβ3 Receptor Antagonist:  Different but Biologically Equivalent. Bioconjugate Chemistry, 2004, 15, 235-241.	3.6	56
88	The role of coordination chemistry in the development of target-specific radiopharmaceuticals. Chemical Society Reviews, 2004, 33, 445.	38.1	326
89	MicroPET imaging of breast cancer ?-integrin expression with Cu-labeled dimeric RGD peptides. Molecular Imaging and Biology, 2004, 6, 350-359.	2.6	190
90	Synthesis, Characterization, and X-ray Crystal Structure of In(DOTA-AA) (AA =p-Aminoanilide):Â A Model for1111n-Labeled DOTA-Biomolecule Conjugates. Inorganic Chemistry, 2003, 42, 8831-8837.	4.0	44

#	Article	IF	CITATIONS
91	Ascorbic Acid:Â Useful as a Buffer Agent and Radiolytic Stabilizer for Metalloradiopharmaceuticals. Bioconjugate Chemistry, 2003, 14, 1052-1056.	3.6	54
92	99mTc-Labeling of a Hydrazinonicotinamide-Conjugated LTB4Receptor Antagonist Useful for Imaging Infection and Inflammation. Bioconjugate Chemistry, 2002, 13, 881-886.	3.6	30
93	Bifunctional Chelators for Therapeutic Lanthanide Radiopharmaceuticals. Bioconjugate Chemistry, 2001, 12, 7-34.	3.6	341
94	99mTc-Labeling of a Hydrazinonicotinamide-Conjugated Vitronectin Receptor Antagonist Useful for Imaging Tumors. Bioconjugate Chemistry, 2001, 12, 624-629.	3.6	78
95	90Y and 177Lu Labeling of a DOTA-Conjugated Vitronectin Receptor Antagonist Useful for Tumor Therapy. Bioconjugate Chemistry, 2001, 12, 559-568.	3.6	59
96	Radio-LC-MS for the Characterization of 99mTc-Labeled Bioconjugates. Bioconjugate Chemistry, 2000, 11, 113-117.	3.6	34
97	99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. Chemical Reviews, 1999, 99, 2235-2268.	47.7	515
98	Technetium Complexes of a Hydrazinonicotinamide-Conjugated Cyclic Peptide and 2-Hydrazinopyridine:Â Synthesis and Characterization. Inorganic Chemistry, 1999, 38, 1326-1335.	4.0	48
99	99mTc-Labeling of Hydrazones of a Hydrazinonicotinamide Conjugated Cyclic Peptide. Bioconjugate Chemistry, 1999, 10, 803-807.	3.6	34
100	RP463:Â A Stabilized Technetium-99m Complex of a Hydrazino Nicotinamide Derivatized Chemotactic Peptide for Infection Imaging. Bioconjugate Chemistry, 1999, 10, 884-891.	3.6	36
101	A Novel Ternary Ligand System for99mTc-Labeling of Hydrazino Nicotinamide-Modified Biologically Active Molecules Using Imine-N-Containing Heterocycles as Coligands. Bioconjugate Chemistry, 1998, 9, 583-595.	3.6	67
102	Biological Evaluation of Thrombus Imaging Agents Utilizing Water Soluble Phosphines and Tricine as Coligands When Used To Label a Hydrazinonicotinamide-Modified Cyclic Glycoprotein IIb/IIIa Receptor Antagonist with99mTc. Bioconjugate Chemistry, 1997, 8, 155-160.	3.6	53
103	New and Versatile Ternary Ligand System for Technetium Radiopharmaceuticals:Â Water Soluble Phosphines and Tricine as Coligands in Labeling a Hydrazinonicotinamide-Modified Cyclic Glycoprotein IIb/IIIa Receptor Antagonist with99mTc. Bioconjugate Chemistry, 1997, 8, 146-154.	3.6	107
104	Labeling a Hydrazino Nicotinamide-Modified Cyclic IIb/IIIa Receptor Antagonist with99mTc Using Aminocarboxylates as Coligands. Bioconjugate Chemistry, 1996, 7, 63-71.	3.6	136
105	Labeling Cyclic Glycoprotein IIb/IIIa Receptor Antagonists with99mTc by the Preformed Chelate Approach:A Effects of Chelators on Properties of [99mTc]Chelatorâ^'Peptide Conjugates. Bioconjugate Chemistry, 1996, 7, 196-202.	3.6	73
106	Biological Evaluation of99mTc-Labeled Cyclic Glycoprotein IIb/IIIa Receptor Antagonists in the Canine Arteriovenous Shunt and Deep Vein Thrombosis Models:Â Effects of Chelators on Biological Properties of [99mTc]Chelatorâ ``Peptide Conjugates. Bioconjugate Chemistry, 1996, 7, 203-208.	3.6	47